Sort   by:  
 Page size 
In castration-resistant prostate cancer (CRPC), clinical response to androgen receptor (AR) antagonists is limited mainly due to AR-variants expression and restored AR signaling. The metabolite spermine is most abundant in prostate and it decreases as prostate cancer progresses, but its functions re...
2023-10-11 | MTBLS8034 | MetaboLights
TMT-MS of whole cell lysate collected from 22Rv1 castration-resistant prostate cancer cells treated with 5 µM JG-98 for 4 hours.
ORGANISM(S): Homo Sapiens (human) 
The androgen receptor (AR) is a ligand-inducible transcription factor that mediates androgen action in target tissues. Upon ligand binding, the AR binds to thousands of genomic loci and activates a cell-type specific gene program. Prostate cancer growth and progression depend on androgen-induced AR ...
ORGANISM(S): Homo sapiens 
More effective therapeutic approaches for castration-resistant prostate cancer (CRPC) are urgently needed, thus reinforcing the need to understand how prostate tumors progress to castration resistance. We have established a novel mouse xenograft model of prostate cancer, KUCaP-2, which expresses the...
ORGANISM(S): Homo sapiens 
The spliced variant forms of androgen receptor (AR-Vs) have been identified recently in castration-resistant prostate cancer (CRPC) cell lines and clinical samples. Here we identified the cistrome and transcriptome landscape of AR-Vs in CRPC cell lines and determine the clinical significance of AR v...
ORGANISM(S): Homo sapiens 
The neuroendocrine (NE) phenotype is associated with the development of metastatic castration-resistant prostate cancer (CRPC). Our objective was to characterize the molecular features of the NE phenotype in CRPC. Expression of chromogranin A (CHGA), synaptophysin (SYP), androgen receptor (AR), and ...
ORGANISM(S): Homo sapiens 
Data from ProteomeXchange, PXD ID: PXD000238. File: Batch3_RA14LiverMetr2-35.mzml. Published as part of Proc Natl Acad Sci U S A. 2013 Nov 18 . From the Abstract: {{i}} ... We evaluated active kinases using phosphotyrosine peptide enrichment and quantitative mass spectrometry to identify druggable ...
ORGANISM(S): Human_adenovirus_54,human_adenovirus_a,human_adenovirus_b,human_adenovirus_c,human_adenovirus_d,human_adenovirus_e,human_adenovirus_f,human_adenovirus_g,human_astrovirus,human_bocavirus,human_bocavirus_2,human_bocavirus_3,human_bocavirus_4,human_coronavirus_229e,human_coronavirus_hku1,human_coronavirus_nl63,human_coronavirus_oc43,human_cosavirus_a,human_cosavirus_b,human_cosavirus_d,human_cosavirus_e,human_enteric_coronavirus_4408,human_enterovirus_100,human_enterovirus_a,human_enterovirus_b,human_enterovirus_c,human_enterovirus_d,human_erythrovirus_v9,human_herpesvirus_1,human_herpesvirus_2,human_herpesvirus_3,human_herpesvirus_4_type_1,human_herpesvirus_4_type_2,human_herpesvirus_5,human_herpesvirus_6a,human_herpesvirus_6b,human_herpesvirus_7,human_herpesvirus_8_type_p,human_immunodeficiency_virus_1,human_immunodeficiency_virus_2,human_metapneumovirus,human_papillomavirus_fa75_ki88_03,human_papillomavirus_rtrx7,human_papillomavirus_type_10,human_papillomavirus_type_100,human_papillomavirus_type_101,human_papillomavirus_type_103,human_papillomavirus_type_104,human_papillomavirus_type_105,human_papillomavirus_type_108,human_papillomavirus_type_109,human_papillomavirus_type_112,human_papillomavirus_type_113,human_papillomavirus_type_16,human_papillomavirus_type_24,human_papillomavirus_type_26,human_papillomavirus_type_32,human_papillomavirus_type_34,human_papillomavirus_type_4,human_papillomavirus_type_41,human_papillomavirus_type_48,human_papillomavirus_type_49,human_papillomavirus_type_5,human_papillomavirus_type_50,human_papillomavirus_type_53,human_papillomavirus_type_60,human_papillomavirus_type_63,human_papillomavirus_type_6b,human_papillomavirus_type_7,human_papillomavirus_type_71,human_papillomavirus_type_88,human_papillomavirus_type_9,human_papillomavirus_type_92,human_papillomavirus_type_96,human_papillomavirus_type_98,human_papillomavirus_type_99,human_papillomavirus___1,human_papillomavirus___18,human_papillomavirus___2,human_papillomavirus___54,human_papillomavirus___61,human_papillomavirus___cand90,human_parainfluenza_virus_1,human_parainfluenza_virus_2,human_parainfluenza_virus_3,human_parechovirus,human_parvovirus_4,human_parvovirus_b19,human_picobirnavirus,human_respiratory_syncytial_virus,human_rhinovirus_a,human_rhinovirus_b,human_rhinovirus_c,human_tmev_like_cardiovirus,human_t_lymphotropic_virus_1,human_t_lymphotropic_virus_2,human_t_lymphotropic_virus_4, Human 
The integration of diverse ‘omic’ datasets will increase our understanding of the key signaling pathways that drive disease. Here, we used clinical tissue cohorts corresponding to lethal metastatic castration resistant prostate cancer (CRPC) obtained at rapid autopsy to integrate mutational, transcr...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2017-03-29 | MSV000080776 | MassIVE
Docetaxel-based chemotherapy is the standard first-line therapy in metastatic castration-resistant prostate cancer. However, most patients eventually develop resistance to this treatment. The aim of the study was to identify key molecular genes and networks associated with docetaxel resistance in 2 ...
ORGANISM(S): Homo sapiens 
Castrate-resistant prostate cancer (CRPC) is poorly characterized and heterogeneous and while the androgen receptor (AR) is of singular importance, other factors such as c-Myc and the E2F family also play a role in later stage disease. Here we show that Hes6 is up-regulated in aggressive human prost...
ORGANISM(S): Homo sapiens 
Sort   by:  
 Page size